U.S. Markets close in 4 hrs 1 min

What does U.S. Physical Therapy, Inc.’s (NYSE:USPH) Balance Sheet Tell Us About Its Future?

Asher Wright

Investors are always looking for growth in small-cap stocks like U.S. Physical Therapy, Inc. (NYSE:USPH), with a market cap of US$1.3b. However, an important fact which most ignore is: how financially healthy is the business? Companies operating in the Healthcare industry, even ones that are profitable, are inclined towards being higher risk. Assessing first and foremost the financial health is essential. Here are few basic financial health checks you should consider before taking the plunge. Though, I know these factors are very high-level, so I’d encourage you to dig deeper yourself into USPH here.

Does USPH produce enough cash relative to debt?

USPH has shrunken its total debt levels in the last twelve months, from US$63m to US$59m – this includes long-term debt. With this debt payback, the current cash and short-term investment levels stands at US$32m for investing into the business. Moreover, USPH has produced US$70m in operating cash flow during the same period of time, resulting in an operating cash to total debt ratio of 117%, signalling that USPH’s debt is appropriately covered by operating cash. This ratio can also be interpreted as a measure of efficiency as an alternative to return on assets. In USPH’s case, it is able to generate 1.17x cash from its debt capital.

Can USPH pay its short-term liabilities?

Looking at USPH’s US$47m in current liabilities, it appears that the company has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 1.93x. Usually, for Healthcare companies, this is a suitable ratio since there is a bit of a cash buffer without leaving too much capital in a low-return environment.

NYSE:USPH Historical Debt January 1st 19

Can USPH service its debt comfortably?

With a debt-to-equity ratio of 17%, USPH’s debt level may be seen as prudent. USPH is not taking on too much debt commitment, which can be restrictive and risky for equity-holders. We can check to see whether USPH is able to meet its debt obligations by looking at the net interest coverage ratio. A company generating earnings before interest and tax (EBIT) at least three times its net interest payments is considered financially sound. In USPH’s, case, the ratio of 6.78x suggests that interest is appropriately covered, which means that debtors may be willing to loan the company more money, giving USPH ample headroom to grow its debt facilities.

Next Steps:

USPH’s high cash coverage and low debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow. In addition to this, the company exhibits an ability to meet its near term obligations should an adverse event occur. This is only a rough assessment of financial health, and I’m sure USPH has company-specific issues impacting its capital structure decisions. You should continue to research U.S. Physical Therapy to get a better picture of the stock by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for USPH’s future growth? Take a look at our free research report of analyst consensus for USPH’s outlook.
  2. Valuation: What is USPH worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether USPH is currently mispriced by the market.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

  • Billionaire George Soros Snaps Up These 3 “Strong Buy” Stocks
    Business
    TipRanks

    Billionaire George Soros Snaps Up These 3 “Strong Buy” Stocks

    George Soros may be a lightning rod for political controversy, but everyone can agree that he's a market and financial genius. In recent years, Soros has made public predictions on the move to regulate internet giants Facebook and Google as public utilities, on the 'bubble' nature of cryptocurrency, and on the Democrats' off-year victory in the 2018 elections. Soros has a positive genius for finding them, and reaping their gains.

  • No shaking hands at London conference after coronavirus scare
    World
    Yahoo Finance UK

    No shaking hands at London conference after coronavirus scare

    Attendees of a conference in central London have been told not to shake hands, weeks after a British person with coronavirus attended an event at the same venue. Guests at the Make UK manufacturing conference in Westminster were told on Tuesday to avoid shaking hands with others. TV presenter Steph McGovern was comparing the event and made the announcement at the start of the conference.

  • Suze Orman says investors should ‘rejoice’ at the Dow’s more-than-1,000-point tumble on Monday — here’s why
    Business
    MarketWatch

    Suze Orman says investors should ‘rejoice’ at the Dow’s more-than-1,000-point tumble on Monday — here’s why

    Author and personal-finance expert Suze Orman had a simple two-word answer to the question of how to react to a market that just shed more than 1,000 points on the back of growing uncertainties, including the spread of the coronavirus outbreak. Orman said Monday on CNBC that investors should stay the course and explained why she thought investors worried about their retirement savings after a historic downturn for the Dow Jones Industrial Average should welcome such selloffs.

  • Pompeo Criticizes Iran, China; Gilead Drug Trials: Virus Update
    World
    Bloomberg

    Pompeo Criticizes Iran, China; Gilead Drug Trials: Virus Update

    Iran reported a total of 15 deaths from the outbreak, the most fatalities outside China, and a top health official tested positive. Italy reported a surge in infections and Spanish police isolated 1,000 people at an island resort. U.S. Secretary of State Michael Pompeo criticized Iran and China's handling of the the virus.

  • Business
    NerdWallet

    How the IRS Knows If You Cheat on Your Taxes

    Those forms, called information returns, typically are records of certain payments you received or made during the tax year that you usually need to report on your tax return. Some of the most common information returns are W-2s, which report wages earned from a job, and 1099s, which report money received for things such as freelance work, dividends or interest. But other money moves you make could put information returns in the IRS' mailbox, too, says Ignatius Jackson, a certified public accountant in Phoenix.

  • Mike Bloomberg has done an about-face on Wall Street reform
    Business
    Yahoo Finance

    Mike Bloomberg has done an about-face on Wall Street reform

    MIA on banking reform — or taking the side of industry For instance, he promises to toughen bank capital rules so that big banks do not collapse under the weight of their own debt obligations, as they did during the 2008 financial crisis. Yet, prior to the crisis, he pushed for weakening bank capital rules through adoption of the so-called “Basel II” accords. Basel II would have released hundreds of billions of equity capital from the U.S. banking system, giving particular relief to banks with large portfolios of mortgages and mortgage-backed securities.

  • 'Flat earther' dies in rocket crash
    U.S.
    Associated Press Videos

    'Flat earther' dies in rocket crash

    A California man who said he wanted to fly to the edge of outer space to see if the world is round has died after his home-built rocket blasted off into the desert sky and plunged back to earth. Feb.

  • Mallinckrodt Unveils $1.6 Billion Opioid Deal — And Generic Stocks Pop
    Business
    Investor's Business Daily

    Mallinckrodt Unveils $1.6 Billion Opioid Deal — And Generic Stocks Pop

    Shares of generic pharmaceutical companies popped Tuesday after Mallinckrodt announced a $1.6 billion opioid settlement and Perrigo gained approval for a new inhaler. In early trading on the stock market today, Mallinckrodt stock launched 25.9%, near 5.30. That prodded Teva Pharmaceutical stock up 1.9%, near 12.90.

  • The Secure Act upended estate planning and taxes for a lot of people — here’s how to adapt
    Business
    MarketWatch

    The Secure Act upended estate planning and taxes for a lot of people — here’s how to adapt

    About two months ago, I gave a presentation to a group of CPAs, attorneys, and financial professionals on the use of trusts as beneficiaries of retirement plans. Well, please let me apologize to the attendees, because Congress passed the Secure Act, blowing it all up effective Jan. 1. The Secure Act, which was signed by President Trump in December, does a number of things that change the rules around retirement plans.

  • NIO Soars on China Government Deal Bernstein Calls a Bailout
    Business
    Bloomberg

    NIO Soars on China Government Deal Bernstein Calls a Bailout

    But in light of the partnership, the company said it plans to raise more than 10 billion yuan ($1.43 billion). NIO shares soared as much as 34% to $5.19 shortly after the open of regular trading Tuesday in New York. The stock had been slumping since last year, as heavy spending on marketing and splashy showrooms failed to generate demand for its ES8 and ES6 electric sport utility vehicles.

  • Business
    Barrons.com

    The Dow Dropped 1000 Points Monday. Here’s What History Says Happens Next.

    From a technical perspective, the S&P 500 should find support near its Jan. 31 low of 3225.52, according to Macro Risk Advisors' John Kolovos. That's right about where the S&P 500, at 3,225.89, closed, and if that breaks a full-blown correction is likely in play. This is the type of distributive selling that will require a good and proper reset in price, sentiment and or time on a break,” he writes.

  • Based On Its ROE, Is Occidental Petroleum Corporation (NYSE:OXY) A High Quality Stock?
    Business
    Simply Wall St.

    Based On Its ROE, Is Occidental Petroleum Corporation (NYSE:OXY) A High Quality Stock?

    Does Occidental Petroleum Have A Good ROE? Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification.

  • Boeing's First Order For 2020 Comes With This Switch To GE Jet Engines
    Business
    Investor's Business Daily

    Boeing's First Order For 2020 Comes With This Switch To GE Jet Engines

    ANA's deal for Boeing 787 Dreamliners with General Electric engines is the aerospace giant's first commercial order for 2020. Boeing stock fell. The Japanese airline will buy 15 widebody Boeing 787 Dreamliners worth $5 billion at list prices.

  • Business
    Bloomberg

    Rejected by Wall Street, Ford’s CEO Has Support Where It Matters

    If there were any doubts in the crowd about that statement, Hackett underscored it by discussing the early retirement of Joe Hinrichs, a Ford president whom many had seen as a potential successor to the CEO. The comment was a surprising display of force from a man who had just overseen another disappointing quarter that deepened the sell-off in Ford stock during his almost three-year tenure. The reason for such confidence: Hackett, 64, retains the backing of Executive Chairman Bill Ford.

  • Business
    Benzinga

    The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement

    NASDAQ: MYGN) OncoSec Medical Inc (NASDAQ: ONCS) Pacific Biosciences of California (NASDAQ: PACB) Precipio Inc (NASDAQ: PRPO) Pulse Biosciences Inc (NASDAQ: PLSE) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Sangamo Therapeutics Inc (NASDAQ: SGMO) Sellas Life Sciences Group Inc (NASDAQ: SLS) Sesen Bio Inc (NASDAQ: SESN) Stealth BioTherapeutics Corp (NASDAQ: MITO) SurModics, Inc. NASDAQ: SRDX) Taro Pharmaceutical Industries Ltd. (NYSE: TARO) Theratechnologies Inc (NASDAQ: THTX) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Vanda Pharmaceuticals Inc. NASDAQ: VNDA) Zogenix, Inc.

  • Gilead Has A Shot At Battling Coronavirus — But Is GILD Stock A Buy?
    Business
    Investor's Business Daily

    Gilead Has A Shot At Battling Coronavirus — But Is GILD Stock A Buy?

    Gilead Sciences is one of the biggest biotech companies behind Amgen in terms of market valuation. But GILD stock is struggling to make a comeback after years of declining hepatitis C drug sales. Now, Gilead is trying to stake its claim in HIV treatments.

  • Politics
    Bloomberg

    Buttigieg Calls for SALT Cap Removal Ahead of California Primary

    Buttigieg updated his tax plan Monday, adding a plank that would remove the $10,000 limit on so-called SALT deductions for those earning up to $400,000, partially reversing a provision in President Donald Trump's tax law that capped those write-offs, which were previously unlimited. The proposal is likely to play well in high-tax states such as California, New York and New Jersey, Democratic strongholds where local leaders have said the cap hurts residents whose incomes and property values tend to be higher.

  • Zoom Video
    Business
    Investor's Business Daily Video

    Zoom Video

    Zoom Video rebounded higher. Zoom has soared during the virus outbreak as investors see companies using Zoom software rather traveling. Could be a long-lasting trend.

  • 3 Healthcare Stocks Fighting the Coronavirus
    Business
    TipRanks

    3 Healthcare Stocks Fighting the Coronavirus

    We say “hypothetically” as mRNA vaccines have yet to be tested on humans and it's still unclear how effective the new coronavirus vaccine will be. Piper Sandler's Edward Tenthoff is bullish on Moderna and notes that the company is “the leader in developing mRNA medicines. The 5-star analyst expounded, “Moderna and VRC finalized sequences to be used in mRNA-1273 and manufacture of the first clinical batch was completed on February 7th.

  • Why the market suddenly got so worried about coronavirus: Morning Brief
    Business
    Yahoo Finance

    Why the market suddenly got so worried about coronavirus: Morning Brief

    Subscribe The story is now much bigger than China The stock market on Monday got slammed. All three major indexes fell more than 3%. The Dow dropped more than 1,000 points for just the third time in its history.

  • Business
    Barrons.com

    Moderna Stock Is Jumping on Coronavirus Vaccine Progress

    The biotech firm (MRNA)announced Monday night that it had shipped vials of its experimental coronavirus vaccine to the National Institutes of Health for human trials. Shares of Moderna (ticker: MRNA) were up 16% Tuesday morning. The news came amid heightening global worry over the spread of the coronavirus known as Covid-19, which emerged in the Hubei province of China and has spread globally.

  • Business
    MarketWatch

    Energy sector tumbles toward lowest close in 10 years as oil prices fall again

    The energy is suffering another broad selloff, to lead the S&P 500's (spx) 11 key sectors in declines, as crude oil prices fall for a third-straight day amid worries that the global spread of COVID-19 will hurt demand. The SPDR Energy Select Sector ETF (xle) slumped 2.3%, with 27 of 28 components losing ground. That put the sector ETF (XLE) on track for the lowest close since July 2010.

  • Boeing’s Board Needs Overhaul, Not Rejiggering
    Business
    Bloomberg

    Boeing’s Board Needs Overhaul, Not Rejiggering

    Boeing directors Edward Liddy – the former CEO of Allstate Corp. and an interim leader at American International Group Inc. during the financial crisis — and Michael Zafirovski, a former General Electric Co. executive and an adviser to Blackstone Group Inc., will step down. Zafirovski was Boeing's longest-serving director at more than 15 years, while Liddy has been on the board since 2010 following an earlier stint that was disrupted by his appointment at AIG.

  • Mastercard CEO Ajay Banga to step down, insider Miebach tapped
    Business
    Reuters

    Mastercard CEO Ajay Banga to step down, insider Miebach tapped

    Mastercard's chief executive officer of 10 years, Ajay Banga, will step down at the start of the next year, the company said on Tuesday, and be replaced by Chief Product Officer Michael Miebach. Banga, who took charge of the company just after the 2008-09 financial crisis, has seen the payment processor's revenue triple during his tenure as online shopping gained prominence around the world. India-born Banga will take on the role of executive chairman, while Miebach will become the company's president on March 1.

  • Business
    Bloomberg

    Warren Buffett Says Reaching for Yield Is ‘Stupid,’ But a Human Impulse

    “Reaching for yield is really stupid, but it's very human,” Buffett said Monday in an interview on CNBC. Buffett, chairman and chief executive officer of Berkshire Hathaway Inc., was asked about life insurance companies that sell products, such as annuities, that promise higher returns than the rates the companies can earn on investments. Buffett, in his annual letter to shareholders Saturday, discussed his view on repurchases and corporate governance.